menu
    • menu
    [{"orgOrder":0,"company":"Biosidus","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biosidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosidus \/ Biosidus","highestDevelopmentStatusID":"10","companyTruncated":"Biosidus \/ Biosidus"},{"orgOrder":0,"company":"Biosidus","sponsor":"Prestige BioPharma Pte Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biosidus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosidus \/ Biosidus","highestDevelopmentStatusID":"15","companyTruncated":"Biosidus \/ Biosidus"}]

    Find Clinical Drug Pipeline Developments & Deals by Biosidus

    Menu

    Biosidus

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biosidus

                            Argentina arrow
                            Global ChemShow
                            Not Confirmed

                            Biosidus

                            Argentina arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Prestige BioPharma Pte Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Prestige Biopharma, Biosidus in Exclusive License for Tuznue® in Latin America

                            Details : Through the licensing deal for Trastuzumab, an unconjugated antibody targeting receptor protein-tyrosine kinase erbB-2, the agreement aims to advance breast cancer treatment.

                            Product Name : Tuznue

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 26, 2025

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Prestige BioPharma Pte Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biosidus

                            Argentina arrow
                            Global ChemShow
                            Not Confirmed

                            Biosidus

                            Argentina arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Mabxience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            mAbxience and Biosidus Sign CDMO agreement for agalsidase beta in Fabry disease

                            Details : mAbxience will manufacture the biosimilar of Fabrazyme (agalsidase beta), developed by Biosidus, for Fabry disease treatment under the agreement.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            February 05, 2024

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Mabxience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth